Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close.

PRNewsWire • Feb 3, 2026

Are Medical Stocks Lagging Solventum Corporation (SOLV) This Year?

Here is how Solventum (SOLV) and Cronos Group (CRON) have performed compared to their sector so far this year.

Zacks Investment Research • Dec 30, 2025

SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio

Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.

Zacks Investment Research • Dec 24, 2025

Solventum Completes Acquisition of Acera Surgical

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S. Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency ST. PAUL, Minn.

PRNewsWire • Dec 23, 2025

Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy

New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care Solventum™  Prevena™ Therapy is the only closed incision negative pressure therapy system with fully integrated linear and area dressings solely indicated for closed incisions that utilize ROCF technology ST. PAUL, Minn.

PRNewsWire • Dec 17, 2025

Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength

ST. PAUL, Minn. , Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC), the highest recognition for supply chain strength in healthcare.

PRNewsWire • Dec 16, 2025

Solventum's Self-Help Is Ahead Of Schedule, But Sentiment Is Not

Solventum offers an interesting risk/reward profile, with improving margins, disciplined reinvestment, and potential revenue growth acceleration offsetting modest core revenue growth concerns. The $725M+ Acera Surgical acquisition provides entry into a double-digit growth wound care market, though it introduces operating and sentiment risks. SOLV's 'Transform for the Future' initiative targets $500M annual cost savings, aiming to boost operating margins above 23% by 2028.

Seeking Alpha • Dec 12, 2025

These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them?

New markets are opening up for Albemarle's lithium products. Recent 3M spinoff Solventum is finding its footing.

The Motley Fool • Dec 5, 2025

Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Seeking Alpha • Dec 2, 2025

Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity

Three stocks that are performing well in 2025 just made notable buyback announcements. All three have achieved returns north of 20% this year, beating the 18% return of the S&P 500 Index.

MarketBeat • Dec 1, 2025